Tempus AI, a technology platform leveraging AI to advance precision medicine and patient care, recently announced its plans to acquire Personalis, a company specializing in early detection of small traces of cancer recurrence. The acquisition will add Personalis’ molecular residual disease, or MRD, technology to the Tempus platform, strengthening the company’s ability to support patients across their cancer journeys.
This move builds on an existing partnership between the two companies, in which Tempus invested in Personalis to commercialize the latter’s NeXT Personal MRD test. By combining Tempus’ multimodal data platform, AI capabilities and precision oncology portfolio with Personalis’ tumor-informed MRD technology, this acquisition is expected to expand access to longitudinal monitoring, help advance biomarker discovery and improve personalized cancer care.
“MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs,” Eric Lefkofsky, Tempus’ CEO, said in a statement. “Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well-positioned to capture this opportunity.”
